Baxdrostat is approved—but the bigger primary care shift is the screening that comes before the script

For years, resistant hypertension has felt like one of medicine’s most stubborn recurring plotlines. 

Patients show up on two, three, sometimes four antihypertensives, and their blood pressure still refuses to cooperate. Clinicians tweak doses, add another agent, reinforce lifestyle counseling, and often find themselves circling the same problem months later.

The approval introduces an entirely new mechanism of action to the hypertension toolbox—and the blood pressure reductions seen in the phase 3 BaxHTN trial are certainly attention-grabbing. ^[]

But if you ask what change is likely to affect the most primary care visits over the next year, the answer may not be baxdrostat itself. It may be the screening that happens before anyone writes the prescription.

A new target in resistant hypertension

Baxdrostat works by selectively inhibiting the CYP11B2 gene, which is responsible for aldosterone synthesis. ^[]That’s important because excess aldosterone has long been recognized as a major driver of resistant hypertension, yet clinicians have had relatively limited options for targeting it directly.

Mineralocorticoid receptor antagonists remain effective tools, but they work downstream of aldosterone production. Baxdrostat takes aim at the source. ^[]

Those numbers are difficult to ignore, especially in a population where every additional reduction in blood pressure can translate into meaningful cardiovascular risk reduction.

“We have been waiting for an innovative medication like BAXFENDY for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension,” said Bryan Williams, MD. ^[]

That doesn’t mean monitoring goes away. Hyperkalemia and hyponatremia emerged as the key adverse effects in clinical studies, meaning electrolyte surveillance will become part of the routine for patients started on therapy. ^[]

Clinicians considering the drug will need to establish clear follow-up pathways for monitoring potassium and sodium, particularly during initiation and dose adjustments.

The guideline change that may matter more

The more consequential shift, however, arrived not from the FDA but from the latest hypertension guidelines.

That’s a substantial departure from the traditional approach, where many clinicians reserved primary aldosteronism testing for patients with particularly severe hypertension, unexplained hypokalemia, or highly suggestive clinical presentations.

The new recommendation effectively broadens the funnel. Suddenly, a much larger segment of the hypertension population becomes eligible for evaluation. ^[]

For many primary care physicians, this may represent a larger workflow disruption than the arrival of any single drug.

Resistant hypertension may be less ‘essential’ than we thought

The growing focus on primary aldosteronism reflects a broader realization that the condition is probably underdiagnosed.

The challenge has never been treatment alone. It’s recognition. Many patients spend years accumulating antihypertensive medications before anyone investigates whether excess aldosterone is driving the problem.

The new screening recommendations are essentially an attempt to move that evaluation earlier in the disease course. ^[] And that’s where baxdrostat enters the picture. A drug designed specifically to target aldosterone production naturally increases interest in identifying the patients most likely to benefit from that pathway.

The real question for primary care 

The practical question isn’t, “Will you prescribe baxdrostat?” It’s, “Are your workflows ready for the patients who may qualify for it?”

These aren’t the most exciting questions, but they may have the biggest impact. While only a subset of patients will ultimately receive baxdrostat, the guideline recommendations potentially touch every stage II hypertension patient on a clinician’s panel. ^[]

Your takeaway 

Baxdrostat’s approval is noteworthy because it introduces the first new antihypertensive mechanism in years aimed directly at aldosterone synthesis. ^[] For patients with resistant hypertension, it offers another option beyond simply stacking additional medications.

But the larger story may be diagnostic rather than therapeutic. The combination of a new aldosterone-targeting drug and expanded primary aldosteronism screening recommendations signals a shift in how clinicians are expected to think about uncontrolled hypertension. 

Rather than assuming resistant hypertension is simply difficult-to-treat essential hypertension, the emphasis is increasingly on asking why blood pressure remains elevated in the first place. ^[]

In that sense, the most important action item may not be learning a new prescription. It may be building a new workup pathway.